Genmab A/S Dkk (GNMSF) 182.0500 $GNMSF Genmab Enters

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genmab A/S Dkk (GNMSF) 182.0500 $GNMSF

Genmab Enters Commercial License Agreement with Gilead for DuoBody(R) Technology
GlobeNewswire - Wed Aug 10, 12:08PM CDT
Company Announcement
GEN: 2.00 (-0.01)

Genmab Announces Financial Results for the First Half of 2016 and Improves 2016 Financial Guidance
GlobeNewswire - Tue Aug 09, 10:11AM CDT
Interim Report for First Half 2016

Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:05AM CDT
Will drug stocks Mylan, Incyte and Genmab be able to pull a surprise when they report Q2 results on Aug 9?
JNJ: 123.22 (-0.55), INCY: 81.05 (-0.16), MYL: 48.46 (-0.25), NVS: 82.08 (-0.72)

Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 11:17AM CDT
Genmab (GNMSF) announced that CHMP issued a negative opinion for Arzerra as a maintenance therapy for relapsed chronic lymphatic leukemia.
JNJ: 123.22 (-0.55), ANIP: 69.58 (+0.48), NVS: 82.08 (-0.72)

Genmab Provides Update on Marketing Authorization Application for Arzerra(r) (ofatumumab) as Maintenance Therapy for Patients with Relapsed CLL
GlobeNewswire - Thu Jun 23, 9:33AM CDT
-- Committee for Medicinal Products for Human Use (CHMP) issues negative opinion for Arzerra for maintenance treatment of patients with relapsed CLL
GEN: 2.00 (-0.01), NVS: 82.08 (-0.72)

7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 51.98 (-0.09), JNJ: 123.22 (-0.55), PFE: 34.98 (-0.17), LGND: 113.94 (-0.77), BMY: 60.63 (-0.34), AMPH: 18.10 (-0.56)

Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis
GlobeNewswire - Thu Jun 02, 12:50AM CDT
Company Announcement

Genmab Achieves USD 30 Million Milestone in DARZALEX(r) (daratumumab) Collaboration with Janssen
GlobeNewswire - Mon May 30, 10:00AM CDT
Company Announcement

Genmab Announces European Conditional Marketing Authorization for DARZALEX(r) (daratumumab) for Multiple Myeloma
GlobeNewswire - Mon May 23, 6:15AM CDT
Company Announcement

Genmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Wed May 18, 12:29PM CDT
Company Announcement

Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL accepted for priority review by FDA
GlobeNewswire - Tue May 17, 3:41PM CDT
Company Announcement
GEN: 2.00 (-0.01)

Genmab Announces Financial Results for the First Quarter of 2016
GlobeNewswire - Tue May 10, 10:15AM CDT
Interim Report for the First Quarter of 2016

Genmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting
GlobeNewswire - Wed Apr 20, 9:53AM CDT
Company Announcement

Patent Infringement Lawsuit Filed Against Genmab and Janssen in the United States Regarding DARZALEX(r)
GlobeNewswire - Mon Apr 04, 1:10PM CDT
Company Announcement

Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement
GlobeNewswire - Mon Apr 04, 10:48AM CDT
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. This patent, which is owned by MorphoSys, describes and claims antibodies with particular features that bind to CD38.

CHMP Issues Positive Opinion Recommending DARZALEX(r) (daratumumab) for Relapsed and Refractory Multiple Myeloma
GlobeNewswire - Fri Apr 01, 10:46AM CDT
-- CHMP issued positive opinion for DARZALEX for relapsed and refractory multiple myeloma

First Phase 3 Trial of Daratumumab in Combination with Standard Therapy in Relapsed/Refractory Multiple Myeloma Meets Primary Endpoint in Planned Interim Analysis
PR Newswire - Wed Mar 30, 11:22AM CDT
Janssen Research & Development, LLC announced today positive results of a pre-planned interim analysis of the Phase 3 MMY3004 (CASTOR) trial evaluating the efficacy and safety of daratumumab, a CD38-directed monoclonal antibody (mAb), in combination with bortezomib and dexamethasone, compared to bortezomib and dexamethasone alone, in patients with relapsed or refractory multiple myeloma. The interim analysis, conducted by an Independent Data Monitoring Committee (IDMC), found that the daratumumab combination treatment regimen improved progression-free survival (PFS) compared with bortezomib and dexamethasone alone, achieving the primary study endpoint (p < 0.0001). Based on the recommendation of the IDMC, the study will be stopped early. Study patients originally assigned to the standard treatment group (bortezomib plus dexamethasone) will be offered the option of receiving daratumumab following confirmed disease progression. All patients continue to be followed for long-term safety and overall survival.

Genmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Wed Mar 30, 11:19AM CDT
Company Announcement

J&J, Roche Tie Up to Study Dual Immunotherapy Combination
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:40PM CDT
Johnson & Johnson (JNJ) inks a clinical trial deal with Roche (RHHBY) to assess dual monoclonal antibody combination therapy.
JNJ: 123.22 (-0.55), AMGN: 173.02 (+0.59)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

C3EL Expands Federal Footprint with Strategic Contracts

Updated Category News Views 3

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

Continue Reading
Vitamin Angels Drives Global Nutrition Advancements

Updated Category News Views 5

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

Continue Reading
Duke Energy's Cost-Protection Plan Shields Ratepayers

Updated Category News Views 3

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

Continue Reading
Ornellaia's 2026 Harvest: Adapting to Nature's Whims

Updated Category News Views 5

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

Continue Reading
Merit Expands in New York with Bold Acquisition Move

Updated Category News Views 3

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

Continue Reading
EMCO's New Automated Facility Could Shake Industry

Updated Category News Views 7

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

Continue Reading
Gong, Agentforce, Avoma Crowned 2026 CI Champions

Updated Category News Views 3

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

Continue Reading
U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Updated Category News Views 3

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

Continue Reading
OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

Updated Category News Views 9

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

Continue Reading
Wally Disrupts Dental Industry with $25M Funding

Updated Category News Views 4

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

Continue Reading

Top 5 Most Recently Viewed Articles

Harley-Davidson Reports Financial Results and Future Strategy

Updated Category News Views 148

Harley-Davidson's Financial Performance Overview Harley-Davidson, Inc. ('Harley-Davidson,' 'HDI,' or the 'Company') (NYSE: HOG) has released its fourth quarter and full year results for 2025. The report outlines the challenges faced during the year and reflects the company’s commitment to stabilizing its operations while aligning production with retail demand. President...

Continue Reading
Burford Capital Analyzes Innovations Transforming Legal Finance

Updated Category News Views 260

Innovative Strategies in Legal Finance for 2025 Burford Capital, a leader in global finance and asset management focused on legal matters, recently released its latest edition of the Burford Quarterly. This insightful journal delves into the significant trends driving innovation in commercial disputes and legal finance, essential for businesses navigating the complexities...

Continue Reading
United Bank Secures Crucial $75M Tax Credit for Growth

Updated Category News Views 116

United Bank Receives Significant Tax Credit Allocation United Bank is excited to share that it has been awarded a substantial allocation of $75 million under the New Markets Tax Credit (NMTC) program. This funding, granted by the Department of the Treasury through its affiliated Community Development Entity, UB Community Development, is a testament to the bank's ongoing...

Continue Reading
Innovative Research Boosts Aptamer Technology by Ajinomoto

Updated Category News Views 235

Advancements in Nucleic Acid Aptamer Technology Ajinomoto Co., Inc. has teamed up with RIBOMIC Inc., a promising biotech firm, to enhance the pharmacokinetics of nucleic acid aptamers using its proprietary AJICAP® technology. This collaboration is aimed at revolutionizing the development of aptamer pharmaceuticals. Understanding AJICAP® and Its Applications The...

Continue Reading
Lucas GC Limited Sees Significant Share Price Jump

Updated Category News Views 150

Lucas GC Limited's Impressive Pre-Market Surge Shares of Lucas GC Limited (NASDAQ: LGCL) experienced a remarkable increase in pre-market trading as the company revealed its financial results for the first half of the fiscal year 2025. This growth can be attributed to the solid performance demonstrated by the company in terms of earnings, alongside a significant increase...

Continue Reading